Catalyst Event
Sino Biopharmaceutical Ltd (1177) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
6/4/2026, 12:00:00 AM
The company presented positive Phase III trial data for its 'Defu Combination' (Anlotinib plus Bemotuzumab) as a first-line treatment for non-squamous non-small cell lung cancer (nsq-NSCLC) at the 2026 ASCO meeting, showing a significant 6-month improvement in median Progression-Free Survival (mPFS) compared to the control group.
Korean Translation
2026년 미국임상종양학회(ASCO)에서 비편평 비소세포폐암(nsq-NSCLC) 1차 치료제로서 '더푸 콤비네이션'(안로티닙+베모투주맙)의 긍정적인 3상 임상 데이터를 발표했으며, 대조군 대비 무진행 생존기간 중앙값(mPFS)이 6개월 유의미하게 개선되었음을 보임.
Related Recent Events
Ambu A/S (AMBUB) · Earnings Release
Q3 2025/26 earnings release scheduled. (Low importance estimated for a routine scheduled event).
8/26/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
Q2 2026 earnings results and conference call for July 29, 2026, before market open scheduled
7/29/2026, 12:00:00 AM
Integer Holdings Corp (ITGR) · Earnings Release
Analysts forecast the next quarterly earnings release for 2026-07-23 estimated. Estimated Medium importance as earnings reports typically drive significant price volatility.
7/23/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM